Table 1 Clinical characteristics at baseline of the children with pediatric neuroblastoma between recurrence and non-recurrence group during 5 years follow-up

Gender

Male

79 (48.5%)

57 (55.9%)

0.258

Female

84 (51.5%)

45 (44.1%)

Age

< 18 months

76 (46.6%)

38 (37.3%)

0.161

≥ 18 months

87 (53.4%)

64 (62.7%)

INSS stage

I

42 (25.8%)

15 (14.7%)

0.001

II

56 (34.3%)

21 (20.6%)

III

38 (23.3%)

39 (38.2%)

IV

27 (16.6%)

27 (26.5%)

Primary site

Mediastinum

32 (19.6%)

28 (27.5%)

0.177

Adrenal

79 (48.5%)

36 (35.3%)

Abdomen

39 (23.9%)

30 (29.4%)

Others

13 (8.0%)

8 (7.8%)

MYCN

Normal

112 (68.7%)

59 (57.8%)

0.086

Amplified

51 (31.3%)

43 (42.2%)

Treatment

Surgery

163 (100%)

102 (100%)

1

Chemotherapy

163 (100%)

102 (100%)

1

Radiotherapy

59 (36.2%)

48 (47.1%)

0.095

Serum LDH (U/L)

628.12 ± 193.43

674.64 ± 237.51

0.108

Serum HVA (µmol/L)

56.16 ± 20.45

72.28 ± 24.02

0.084

Serum ferritin (ng/mL)

148.32 ± 47.48

269.81 ± 62.97

0.006

Serum CA125 (U/ml)

55.84 ± 26.06

82.20 ± 37.01

< 0.001

Serum NSE (ng/mL)

51.02 ± 25.54

75.06 ± 31.51

< 0.001

24-hour urine VMA (µmol/L)

67.28 ± 30.46

111.22 ± 49.48

< 0.001

Recurrence pattern

Local relapse

-

73 (71.6%)

-

CNS metastasis

4 (3.9%)

Bone metastasis

9 (8.8%)

Bone marrow metastasis

7 (6.9%)

Pulmonary metastasis

3 (2.9%)

Pelvic metastasis

6 (5.9%)